Cyclo Historical Cash Flow
| CYTH Stock | USD 0.60 0.02 2.81% |
Analysis of Cyclo Therapeutics cash flow over time is an excellent tool to project Cyclo Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 3.2 M or Begin Period Cash Flow of 2 M as it is a great indicator of Cyclo Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Cyclo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclo Therapeutics is a good buy for the upcoming year.
Cyclo |
About Cyclo Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Cyclo balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cyclo's non-liquid assets can be easily converted into cash.
Cyclo Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Cyclo Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cyclo Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Cyclo Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Other Cashflows From Financing Activities is increasing as compared to previous years. The Cyclo Therapeutics' current Other Non Cash Items is estimated to increase to about 61.1 K, while Change To Inventory is forecasted to increase to (50.1 K).
Cyclo Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Cyclo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclo Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 160.6K | 4.7K | 10.5K | (27.1K) | (52.8K) | (50.1K) | |
| Change In Cash | 566.3K | 10.1M | 3.8M | (15.1M) | 7.7M | 8.1M | |
| Free Cash Flow | (6.6M) | (8.6M) | (15.0M) | (15.1M) | (16.2M) | (15.4M) | |
| Change In Working Capital | 487.4K | 117.3K | (1.2M) | (48.2K) | 3.1M | 3.2M | |
| Begin Period Cash Flow | 2.2M | 2.8M | 12.8M | 16.6M | 1.5M | 2.0M | |
| Other Cashflows From Financing Activities | 130.1K | (14.0K) | 14.8K | 38.2K | 14.2M | 14.9M | |
| Depreciation | 5.7K | 12.8K | 16.8K | 19.5K | 19.3K | 18.3K | |
| Other Non Cash Items | 13.3K | 74.7K | 21.9K | (148.3K) | 52.9K | 61.1K | |
| Capital Expenditures | 1.3K | 53.1K | 22.5K | 15.1K | 2.4K | 2.3K | |
| Total Cash From Operating Activities | (6.6M) | (8.5M) | (15.0M) | (15.1M) | (16.2M) | (15.4M) | |
| Net Income | (7.5M) | (8.9M) | (14.3M) | (15.5M) | (20.1M) | (19.1M) | |
| Total Cash From Financing Activities | 7.1M | 18.6M | 18.8M | 6.8K | 23.9M | 25.1M | |
| End Period Cash Flow | 2.8M | 12.8M | 16.6M | 1.5M | 9.2M | 9.7M | |
| Stock Based Compensation | 436.7K | 271.3K | 470.9K | 513.6K | 736.9K | 773.8K | |
| Change To Account Receivables | (63.4K) | 72.4K | (444.0K) | 427.9K | (67.4K) | (64.0K) | |
| Investments | 36.1K | (14.0K) | 14.8K | 38.2K | (2.4K) | (2.3K) | |
| Total Cashflows From Investing Activities | 36.1K | (14.0K) | 14.8K | 38.2K | 34.4K | 32.6K | |
| Change To Operating Activities | (728.9K) | (104.8K) | (1.2M) | (248.6K) | (223.7K) | (234.9K) | |
| Change To Netincome | 433.0K | 271.3K | 492.8K | 365.3K | 328.8K | 316.3K | |
| Change To Liabilities | 1.1M | 145.0K | 408.2K | (200.4K) | (180.4K) | (171.3K) | |
| Issuance Of Capital Stock | 7.0M | 18.5M | 18.8M | 4.2M | 9.2M | 11.3M |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.